血管生成
祖细胞
内皮干细胞
小RNA
内皮
内皮祖细胞
治疗性血管生成
脐静脉
内皮功能障碍
血管生成
生物
细胞生物学
炎症
电池类型
医学
生物信息学
癌症研究
免疫学
细胞
新生血管
干细胞
内分泌学
遗传学
体外
基因
作者
Tanja Ćelić,Valérie Metzinger-Le Meuth,Isabelle Six,Ziad A. Massy,Laurent Metzinger
出处
期刊:Current Vascular Pharmacology
[Bentham Science]
日期:2016-11-14
卷期号:15 (1): 40-46
被引量:46
标识
DOI:10.2174/1570161114666160914175149
摘要
The discovery of small RNAs has shed new light on microRNA (mRNA) regulation and a range of biological processes. The recognition that miRNAs-221 and -222 are sensitive regulators in the endothelium may enable the identification of novel biomarkers and therapeutic targets. Given that endothelial dysfunction precedes the development of atherosclerosis and contributes to the development of cardiovascular damage, circulating miRNAs produced by Endothelial Cells (ECs) are putative biomarkers for a wide range of cardiovascular diseases. Furthermore, EC proliferation and migration have a critical role in the formation of new blood vessels (angiogenesis), an important component of physiological processes and tumour growth. Hence, the use of anti-angiogenic miRNAs might constitute a novel therapeutic strategy. Along with endothelial angiogenesis, several other processes involving ECs (such as neointimal lesion formation, vascular inflammation, lipoprotein metabolism and hypertension) are critical factors in atherogenesis and atherosclerosis. The fact that human blood-derived progenitor cells, endothelial progenitor cells, umbilical vein ECs and quiescent ECs express high levels of miR-221/222 suggests an important role for this miRNA cluster in endothelial (patho) physiology. The present article reviews current knowledge on miRNAs-221/222's regulation roles in endothelial function and disease in general and angiogenesis in particular.
科研通智能强力驱动
Strongly Powered by AbleSci AI